Premium
Lyme borreliosis treatment
Author(s) -
Vaňousová Daniela,
Hercogová Jana
Publication year - 2008
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2008.00177.x
Subject(s) - medicine , lyme borreliosis , dermatology , lyme disease , erythema chronicum migrans , virology , borrelia burgdorferi , immunology , antibody
Lyme borreliosis is the most common human tick‐borne illness in the Northern Hemisphere. The causative agent is the spirochete Borrelia burgdorferi species complex, and the hard‐shell ticks of the genus Ixodes is responsible for pathogen transmission from animals to humans. The incidence of the disease is increasing year by year and although lyme disease is not fatal, it can affect the skin, heart, nervous, and musculoskeletal system with an impairment of quality of life. The appropriate diagnosis of lyme disease should be promptly treated by antibiotics to prevent late stage of the disease. The choice of antibiotics depends on many factors such as the stage of the disease, the drug efficacy, adverse effects, type of delivery, duration of treatment, and cost. Treatment failure occurs as a result of many reasons, re‐infection is possible. The recommended treatment schedule in the Czech Republic is presented.